Causes and Consequences of Hypertriglyceridemia

High triglycerides are a known marker of cardiovascular risk in type 2 diabetes — but this mechanistic review argues the triglycerides themselves aren’t the culprit. The damage is done by the particles that carry them.

Tracing the biology, the authors show how the insulin-resistant liver overproduces large triglyceride-rich VLDL particles, setting off a cascade that leaves behind cholesterol-rich “remnants” and small, dense LDL — all of them carrying apolipoprotein B, all of them able to lodge in the artery wall. The unifying insight: risk tracks the number of ApoB particles, not the triglyceride content. Elevated triglycerides are a flag for this dangerous particle population, not the direct cause.

The practical takeaway reaches past LDL-C: in diabetes and metabolic syndrome, measure ApoB or non-HDL cholesterol to catch residual risk that a controlled LDL-C can hide, and use therapies that clear or reduce ApoB particles. The resistance is the entrenched focus on triglycerides and LDL-C as the guideline targets.

We rate the evidence moderate: a rigorous mechanistic synthesis integrating kinetic, genetic, and trial data from leading experts, though a review rather than primary research. Its clinical significance is high — it reframes the residual risk that drives events in the large and growing diabetic population around ApoB.